Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-03-29

Clinical Trial Update: Ciclosporin to Reduce Reperfusion Injury in Primary PCI [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ciclosporin to reduce myocardial reperfusion injury during primary PCI has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ciclosporin (cyclosporine)

Snippet

Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust | Conditions: Myocardial Reperfusion Injury | Phase 2 | Status: COMPLETED